American Bar Association
Health Law and Life Sciences Committee

ABA Section of Business Law

Health Law and Life Sciences Committee

Mission Statement

The mission of the Health Law and Life Sciences Committee is to address legal issues encountered by members of the Business Law Section who serve life science and health care clients and their business associates. The Committee strives to provide valuable content to its members and to promote discussion and interaction among its members. The Committee is actively working increase its membership through its activities. The Committee strives to provide at least three substantive programs annually at various Business Law Section Meetings and to cosponsor programs of interest to the Committee. These meetings will provide an opportunity for members of the Section to discuss legal issues related to the life science and health care industry and help members serve their clients.

Areas of Expertise

The Committee's membership has experience in all facets of corporate and regulatory issues affecting health care providers and life science companies. Areas of expertise include:

  • Life Sciences - Pharmaceutical, Biologic, Medical Device and Human Cell and Tissue Based Products
  • Physicians and other Suppliers
  • Hospitals and Academic Medical Centers
  • Other Health Care Providers and Facilities, including Federally Qualified Health Centers, Pharmacies, Long Term Care,
  • Transactions including Mergers and Acquisitions
  • Business and Finance
  • Restructurings
  • Reimbursement
  • Health Information Technology, including Electronic Health Records
  • Data Privacy and Security
  • Intellectual Property
  • Regulatory and Compliance, including Fraud and Abuse
  • Government Investigations
  • Clinical and Translational Research
  • Personalized Medicine
  • Product Regulation
  • Medical Malpractice and Product Liability
  • Medical Ethics

Member-Submitted Publications

The members of the Health Law and Life Sciences Committee write extensively on topics pertinent to health care providers and life science companies. The following are articles, alerts and analyses of national interest submitted by our members and organized by subject matter. If you are a Committee member and would like to have your article or publication considered for posting on this website, please contact William Roberts, the Health Law and Life Sciences Committee’s Content Director, at

Data Privacy and Security

HIPAA Final Rule
February 12, 2013
Shipman & Goodwin LLP

On January 17, 2013, the U.S. Department of Health and Human Services released the long-anticipated final rule modifying the Health Insurance Portability and Accountability Act’s (“HIPAA”) privacy, security, breach notification and enforcement rules. Covered entities and business associates will have until September 23, 2013 to comply with most of the major provisions of the final rule.

After a Two-And-A-Half Year Wait, HHS Finalizes Modifications to HIPAA Rules: Prepare Now for Changes
January 23, 2013
Bass Berry Sims, PLC

On January 17, 2013, the U.S. Department of Health and Human Services ("HHS") issued the highly anticipated omnibus final rule (the "Final Rule") to modify the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") pursuant to the Health Information Technology for Economic and Clinical Health Act ("HITECH"). Following the enactment of HITECH, HHS issued interim final rules to implement the breach notification requirements and certain of the enforcement provisions of HITECH (collectively, the "Interim Rules"), and in July of 2010 HHS issued a proposed rule to implement modifications to the privacy and security provisions of HIPAA. Since that time, Covered Entities and their Business Associates and subcontractors have been awaiting the Final Rule to confirm the extent to which these modifications, which are aimed primarily at strengthening the privacy and security protections for protected health information ("PHI") and tightening the HIPAA enforcement provisions, will impact their operations, contractual relationships and potential exposure for HIPAA liability.

Life Sciences Corporate & Regulatory

CMS Issues Physician Payments Sunshine Act Final Rule: Reporting Requirements for Manufacturers of Drugs, Devices, Biologicals and Medical Supplies and Group Purchasing Organizations
February 28, 2013
Shipman & Goodwin LLP

The Centers for Medicare and Medicaid Services (CMS) recently issued final regulations to implement the reporting and transparency requirements set forth in the Patient Protection and Affordable Care Act, also known as the Physician Payments Sunshine Act. The final regulations require certain manufacturers of drugs, devices, biologicals or medical supplies to report to CMS certain payments or transfers of value to physicians and teaching hospitals. The Final Rule also requires such manufacturers and certain group purchasing organizations to report certain ownership and investment interests. We have prepared this alert to provide an overview of the requirements imposed by the Final Rule.

Final Sunshine Rule - Get Ready to Start Tracking Data
February 26, 2013
Bass Berry Sims PLC

On February 8, 2013, after a long delay, the Centers for Medicare & Medicaid Services ("CMS") published in the Federal Register the final rule ("Final Rule") implementing the Physician Payment Sunshine Act ("Sunshine Act") enacted pursuant to section 6002 of the Affordable Care Act. The Final Rule, while largely in line with the proposed rule, makes some helpful clarifications and simplifies the requirements for reporting research payments.

FDA Releases Guidance on Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices
June 11, 2012
Shipman & Goodwin LLP

The Food and Drug Administration (FDA) released draft guidance addressing how pharmaceutical and medical device manufacturers and distributors should respond to unsolicited requests for off-label information about their FDA-approved products. The guidance was issued in response to industry feedback from 2009 hearings regarding social media marketing. It is the first of multiple planned policy recommendations by FDA on marketing practices and emerging electronic media.

FDA and HHS Rules on Disclosure of Conflicts of Interest in Research
May 2, 2012
Shipman & Goodwin LLP

The issue of potential conflicts of interests by those engaged in research is not new. However, within the last twelve months, two Federal agencies have published guidance with respect to disclosures of conflicts of interest by those engaged in clinical research. The following sets forth a summary of the current Food and Drug Administration (“FDA”) requirements with respect to financial conflicts of interest and where noted, incorporates provisions of a draft guidance that was issued by the FDA in 2011. The summary also includes the U.S. Department of Health and Human Services (“HHS”) requirements with respect to financial conflicts of interest held by researchers including new provisions that go into effect on August 24, 2012. The summary should be used only as a guide and is not intended to replace the need for you to review the FDA or HHS regulations in their entirety and/or to seek legal counsel with respect to your set of facts as these rules are subject to agency interpretation.

Related Products

Join Us



Maizel, Samuel

Committee Roster  

Sub Committees  (click [+] for listing)

 Sub Committees

Programs, Meetings and Events

Section Events

    M&A Survival Guide to Selling the Closely-Held Business


    Offering a comprehensive introduction to the art and science of selling a closely-held business, the panelists will cover the basic corporate law issues relevant to a private M&A transaction including: transaction structuring auctions and other deal processes to maximize seller leverage key deal ...

    2018 Business Law Section Annual Meeting

    Fairmont Austin

    **PLEASE START HERE FOR REGISTRATION AND TO ADD TICKETED EVENTS (LUNCHES/DINNERS) TO YOUR REGISTRATION** TO ADD EVENTS TO AN EXISTING REGISTRATION: Click on Register Now, which will prompt you to log-in with your ABA credentials. After logging in, click on View Registration. ...

    Negotiating Private Company Acquisitions: The Most Contentious Deal Points


    Three seasoned M&A practitioners from across the country will engage in illustrative negotiations of key representations, walk rights and indemnification provisions in an agreement for the acquisition of a privately held company, in order to illuminate the conflicting positions of sellers and buyers. ...



The Health Law and Life Sciences Committee is committed to realizing the ABA’s diversity goals and has adopted the Business Law Section’s Diversity Plan, a copy of which is available here.

Should you have any questions about the Plan or diversity at the ABA in general, please contact Christopher Carlson, the Health Law Committee's Diversity Director, at



In order to send a message to the listserve, send a message to the email address below. You must be a member of the Committee to successfully send a message to the listserve.

In order to access the listserve archive, please click here.


Modified by Graham Hunt on October 4, 2016

Back to Top